C3 GLOMERULONEPHRITIS

Clinical trials for C3 GLOMERULONEPHRITIS explained in plain language.

Never miss a new study

Get alerted when new C3 GLOMERULONEPHRITIS trials appear

Sign up with your email to follow new studies for C3 GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

New treatment hope for rare kidney disease patients

Disease control APPROVED_FOR_MARKETING

This program provides early access to pegcetacoplan for people with rare kidney diseases called C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The treatment is for patients aged 12 and older who have active kidney disease and…

Matched conditions: C3 GLOMERULONEPHRITIS

Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Apr 02, 2026 05:14 UTC

C3 GLOMERULONEPHRITIS

Get alerted when new C3 GLOMERULONEPHRITIS trials appear

New treatment hope for rare kidney disease patients